UBS Group’s eXoZymes Inc EXOZ Stock Holding History

UBS Group’s Portfolio EXOZ Stock Details EXOZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$180	Buy	24 +21	+700%	+$192	﹤0.01%	10047
2025 Q4	$33	Sell	3 -4,618	-100%	-$63.7K	﹤0.01%	10309
2025 Q3	$66.7K	Sell	4,621 -393	-8%	-$4.28K	﹤0.01%	7372
2025 Q2	$49.5K	Buy	5,014 +4,851	+2,976%	+$59.2K	﹤0.01%	7781
2025 Q1	$1.7K	Sell	163 -544	-77%	-$8.08K	﹤0.01%	9461
2024 Q4	$11.7K	Buy	+707	New	+$10.4K	﹤0.01%	8233

Other funds holding EXOZ

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's EXOZ Position: Q1 2026 in Review

UBS Group increased its eXoZymes Inc (EXOZ) stake by 700% in Q1 2026, buying an estimated $192 and bringing the position to 24 shares worth $180. The position accounts for ﹤0.01% of the portfolio, ranked #10047.

UBS Group first reported a position in EXOZ in Q4 2024 and has held it in 6 quarters since. The position peaked at $66.7K in Q3 2025. 7 funds tracked by Wall St. Rank hold EXOZ as of Q1 2026.

UBS Group held 24 shares of eXoZymes Inc worth $180 as of Q1 2026.
UBS Group bought 21 eXoZymes Inc shares in Q1 2026, an estimated $192.
eXoZymes Inc made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10047 holding.
UBS Group first reported a position in eXoZymes Inc in Q4 2024 and has held it in 6 quarters since.
UBS Group's eXoZymes Inc position peaked at $66.7K in Q3 2025.
7 funds tracked by Wall St. Rank held eXoZymes Inc as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.